000			01622 a2200445 4500
005			20250516025613.0
264		0	_c20111129
008			201111s 0 0 eng d
022			_a1434-9949
024	7		_a10.1007/s10067-011-1704-7 _2doi
040			_aNLM _beng _cNLM
100	1		_aHaroon, Muhammad
245	0	0	_aDevelopment of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association? _h[electronic resource]
260			_bClinical rheumatology _cAug 2011
300			_a1095-8 p. _bdigital
500			_aPublication Type: Case Reports; Journal Article
650	0	4	_aAbatacept
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use
650	0	4	_aAntirheumatic Agents _xadverse effects
650	0	4	_aArthritis, Rheumatoid _xcomplications
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEtanercept
650	0	4	_aHumans
650	0	4	_aImmunoconjugates _xtherapeutic use
650	0	4	_aImmunoglobulin G _xadverse effects
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMethotrexate _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aRadiography, Thoracic
650	0	4	_aReceptors, Tumor Necrosis Factor
650	0	4	_aRituximab
650	0	4	_aSarcoidosis _xdiagnosis
650	0	4	_aTreatment Outcome
700	1		_aRyan, John G
700	1		_aHarney, Sinead
773	0		_tClinical rheumatology _gvol. 30 _gno. 8 _gp. 1095-8
856	4	0	_uhttps://doi.org/10.1007/s10067-011-1704-7 _zAvailable from publisher's website
999			_c20653558 _d20653558